Astra Pharmaceuticals Limited

Astrazeneca Ab

Astra Zeneca U.k. Limited

Peter Richard Hamley

Alan C Tinker

Austen Pimm

Thomas McInally

Stephen Connolly

David R Cheshire

Antonio Mete

James Russell Matz

David Cox

James E MacDonald

Haydn Beaton

There is disclosed the use of a compound of formula (I) wherein R, R, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.

Use of phenylheteroakylamine derivatives

The invention relates to the co-administration of an inhibitor of induced nitric oxide synthase and an inhibitor of cyclooxygenase-2 for the treatment of inflammation and inflammatory disorders.

Pharmaceutical combination comprising a COX-2 inhibitor and a iNOS inhibitor

There are provided novel compounds of formula (I)

Amino-spiro-quinazoline compounds

Spiro-piperidine derivatives as inhibitors of nitric oxide synthase

Compounds

Aminoisoquinolines and aminotheinopyridine derivatives and their use as

Combination

Pharmaceutically active compounds

Growing community of inventors

Rothley, United Kingdom

Peter Richard Hamley